Infinity Pharmaceuticals, Inc. (INFI) said Tuesday that Lawrence Bloch has joined the company as executive vice president, chief financial officer and chief business officer.
In this role, Dr. Bloch is responsible for the company's corporate, financial and business development strategies and operations.
Prior to joining Infinity, Dr. Bloch served as chief executive officer of NeurAxon, Inc., a company focused on developing next-generation pain therapeutics, from 2007 to 2011. Previously, he served as chief business officer and chief financial officer of NitroMed, Inc.
From 1999 to 2004, Dr. Bloch served as chief financial officer and vice president of business development, of Applied Molecular Evolution, Inc., leading the company's $101 million initial public offering and $420 million merger with Eli Lilly and Co.
For comments and feedback: editorial@rttnews.com